Kane Biotech Inc. , a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, will announce its third quarter 2020 financial results after market close on Thursday, November 26, 2020.
Kane Biotech management will host a conference call at 4:30 p.m. ET on Monday Nov. 30, 2020 to review the financial results and discuss business developments in the period.
|Third Quarter 2020 Results Conference Call Details:|
|Date:||Monday November 30, 2020|
|Time:||4:30 p.m. ET|
|Live Call:||1-877-268-9044 (Canada and the United States)|
The call will also be broadcast live and archived on the Company’s website at www.kanebiotech.com under “News/Events” in the Investors section.
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (52 patents and patents pending, trade secrets and trademarks) and products developed by the Company’s own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex™, bluestem™, bluestem®, silkstem™, goldstem™, coactiv+™, coactive+®, DermaKB™ and DermaKB Biofilm™ are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol “KNE” and on the OTCQB Venture Market under the symbol “KNBIF”.
For more information, please visit www.kanebiotech.com, or contact:
Chief Executive Officer
Kane Biotech Inc.
+1 (514) 910-6991
Chief Financial Officer
Kane Biotech Inc.
+1 (204) 298-2200
+1 (416) 842 9003